OTS-167

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C25H28Cl2N4O2
Molecular Weight	487.421
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CN(C)C[C@H]1CC[C@@H](CC1)NC2=C(C=NC3=C2N=C(C=C3)C4=CC(Cl)=C(O)C(Cl)=C4)C(C)=O

InChI

InChIKey=DKZYXHCYPUVGAF-JCNLHEQBSA-N

InChI=1S/C25H28Cl2N4O2/c1-14(32)18-12-28-22-9-8-21(16-10-19(26)25(33)20(27)11-16)30-24(22)23(18)29-17-6-4-15(5-7-17)13-31(2)3/h8-12,15,17,33H,4-7,13H2,1-3H3,(H,28,29)/t15-,17-

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27082996

OTS-167 is a maternal embryonic leucine zipper kinase (MELK) inhibitor which demonstrated antitumor properties in laboratory tests. It is being developed as an anti-cancer drug. The compound has been shown to suppress the growth of breast, lung, pancreatic and prostate cancer cells that express high levels of the MELK protein. OTS167 reached phase II clinical trials in patients with AML, ALL, advanced MDSs, advanced MPNs, or advanced CML and phase I in patients with breast cancer.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Maternal embryonic leucine zipper kinase 4 Target ID: Q14680\|\|\|B7Z6Y0 Gene ID: 9833.0 Gene Symbol: MELK Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/24657156	Inhibitor 8297		0.41 nM [IC50]

Conditions

Condition	Modality	Highest Phase	Product
Acute myeloid leukemia 136 Sources: https://clinicaltrials.gov/ct2/show/NCT02795520	Primary	Phase II 1132	Unknown Approved Use Unknown
Metastatic solid tumors 4 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24795222	Primary	Phase I 428	Unknown Approved Use Unknown
Breast cancer 434 Sources: https://clinicaltrials.gov/ct2/show/NCT02926690	Primary	Phase I 428	Unknown Approved Use Unknown
Acute lymphoblastic leukemia 27 Sources: https://www.clinicaltrials.gov/ct2/show/NCT02795520	Primary	Phase II 1132	Unknown Approved Use Unknown
Myelodysplastic syndromes 58 Sources: https://www.clinicaltrials.gov/ct2/show/NCT02795520	Primary	Phase II 1132	Unknown Approved Use Unknown
Myeloproliferative neoplastic disorders 2 Sources: https://www.clinicaltrials.gov/ct2/show/NCT02795520	Primary	Phase II 1132	Unknown Approved Use Unknown
Chronic myelogenous leukemia 22 Sources: https://www.clinicaltrials.gov/ct2/show/NCT02795520	Primary	Phase II 1132	Unknown Approved Use Unknown

Sourcing

Vendor/Aggregator	ID	URL
Molnova	M11835	https://www.molnova.com/en/serch-list.html?keywords=M11835
eMolecules	195179080	https://orderbb.emolecules.com/search/#?query=195179080
eMolecules	275159368	https://orderbb.emolecules.com/search/#?query=275159368
eMolecules	300756500	https://orderbb.emolecules.com/search/#?query=300756500

PubMed

Title	Date	PubMed
Glucuronidation of OTS167 in Humans Is Catalyzed by UDP-Glucuronosyltransferases UGT1A1, UGT1A3, UGT1A8, and UGT1A10.	2015 Jul	25870101
OTSSP167 Abrogates Mitotic Checkpoint through Inhibiting Multiple Mitotic Kinases.	2016	27082996
Evaluation of human microtubule affinity-regulating kinase 4 inhibitors: fluorescence binding studies, enzyme, and cell assays.	2017 Nov	27748164

Patents

Sample Use Guides

In Vivo Use Guide

In phase I clinical trial on healthy participants OST-167 was given at doses 0.5 mg, 1.0 mg, and 2.0 mg .

Route of Administration: Oral

In Vitro Use Guide

HeLaM or MCF7 cell lines were treated with 100nM OTS-167 for 2 hours to test the effect of the drug on mitosis.

Name

Type

Language

OTS-167

Common Name

English

ETHANONE, 1-(6-(3,5-DICHLORO-4-HYDROXYPHENYL)-4-((TRANS-4-((DIMETHYLAMINO)METHYL)CYCLOHEXYL)AMINO)-1,5-NAPHTHYRIDIN-3-YL)-

Systematic Name

English

OTS167

Code

English

MELK INHIBITOR OTS167

Common Name

English

OTSSP-167

Code

English

OTSSP167

Code

English

Classification Tree Code System Code

NCI_THESAURUS

C61074